DK1397105T3 - Præparat til inhibering af angiogenese - Google Patents

Præparat til inhibering af angiogenese

Info

Publication number
DK1397105T3
DK1397105T3 DK02739332T DK02739332T DK1397105T3 DK 1397105 T3 DK1397105 T3 DK 1397105T3 DK 02739332 T DK02739332 T DK 02739332T DK 02739332 T DK02739332 T DK 02739332T DK 1397105 T3 DK1397105 T3 DK 1397105T3
Authority
DK
Denmark
Prior art keywords
preparation
inhibiting
inhibiting angiogenesis
methods
oleouropein
Prior art date
Application number
DK02739332T
Other languages
English (en)
Inventor
Jeffrey H Tavis
Hamdi K Hamdi
Raquel Castellon
Original Assignee
Hamdi K Hamdi
Jeffrey H Tavis
Raquel Castellon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamdi K Hamdi, Jeffrey H Tavis, Raquel Castellon filed Critical Hamdi K Hamdi
Application granted granted Critical
Publication of DK1397105T3 publication Critical patent/DK1397105T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK02739332T 2001-05-23 2002-05-22 Præparat til inhibering af angiogenese DK1397105T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29294701P 2001-05-23 2001-05-23

Publications (1)

Publication Number Publication Date
DK1397105T3 true DK1397105T3 (da) 2006-11-27

Family

ID=23126933

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02739332T DK1397105T3 (da) 2001-05-23 2002-05-22 Præparat til inhibering af angiogenese

Country Status (16)

Country Link
US (1) US6632798B2 (da)
EP (1) EP1397105B1 (da)
JP (1) JP2005508856A (da)
CN (1) CN1315479C (da)
AT (1) ATE333882T1 (da)
AU (1) AU2002311985B9 (da)
BR (1) BR0209922A (da)
CA (1) CA2447231A1 (da)
DE (1) DE60213407T2 (da)
DK (1) DK1397105T3 (da)
ES (1) ES2266512T3 (da)
IL (1) IL158899A0 (da)
MX (1) MXPA03010528A (da)
PT (1) PT1397105E (da)
WO (1) WO2002094193A1 (da)
ZA (1) ZA200308763B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3629939B2 (ja) * 1998-03-18 2005-03-16 セイコーエプソン株式会社 トランジスタ回路、表示パネル及び電子機器
US20030086986A1 (en) * 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US7468355B2 (en) * 2002-05-22 2008-12-23 H2Rc Corporation Methods for inhibiting cancer and scar formation
FR2853549B1 (fr) * 2003-04-11 2007-11-09 Agronomique Inst Nat Rech Composition nutritionnelle ou therapeutique contenant le compose oleuropeine ou l'un de ses derives
WO2006053415A1 (en) * 2004-11-18 2006-05-26 Biopharmacopae Design International Inc. Plant extract having matrix metalloprotease inhibiting activity and dermatological uses thereof
US20060100368A1 (en) * 2004-11-08 2006-05-11 Park Edward H Elastomer gum polymer systems
WO2007039262A1 (en) * 2005-09-30 2007-04-12 Dsm Ip Assets B.V. Novel compositions containing polyphenols
ES2289897B1 (es) * 2005-11-08 2008-12-16 Laboratorios Belmac, S.A. Composicion para administracion transdermica de agentes fisiologicamente activos.
ES2274721B1 (es) * 2005-11-03 2008-06-01 Laboratorios Belmac, S.A. Nuevo agente terapeutico para el tratamiento de una condicion asociada a la enfermedad vascular periferica.
US8050477B2 (en) * 2006-02-01 2011-11-01 Koninklijke Philips Electronics N.V. Radiation therapy flanning procedure
EP2040696B1 (en) * 2006-07-14 2017-01-25 DSM IP Assets B.V. Compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders
JP5175481B2 (ja) * 2006-10-23 2013-04-03 エーザイフード・ケミカル株式会社 軟骨再生促進剤
KR100834444B1 (ko) * 2007-01-15 2008-06-09 원광대학교산학협력단 물푸레나무로부터 분리된 올레우로페인 화합물을 포함하는톡소플라즈마증 예방 및 치료용 약학조성물
WO2008128552A1 (en) * 2007-04-18 2008-10-30 Dsm Ip Assets B.V. Novel use of hydroxytyrosol and olive extracts/concentrates containing it
ES2343880B8 (es) * 2007-05-10 2011-12-01 Universidad De Malaga Piridotienotriazinas como compuestos antiangiogenicos.
JP5138341B2 (ja) * 2007-11-07 2013-02-06 日本メナード化粧品株式会社 抗アレルギー剤
KR101098952B1 (ko) * 2009-05-08 2011-12-28 한국생명공학연구원 갈잎떨기나무 추출물을 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 조성물
WO2011141611A1 (es) 2010-05-14 2011-11-17 Sanidad Y Residencias 21, S.A., Composiciones de oleuropeína para cicatrización de heridas y úlceras en ancianos y/o diabéticos
ES2349976B1 (es) * 2009-05-14 2011-11-10 Sanidad Y Residencias 21 Sa Utilizacion de extractos de hojas de olivo en una composicion farmaceutica para inducir angiogenesis y vasculogenesis.
US8092843B2 (en) * 2009-09-23 2012-01-10 East Park Research, Inc. Method and composition for cutaneous treatment of herpes simplex infections
ITMI20111042A1 (it) * 2011-06-09 2012-12-10 Flavia Franconi Frazioni standardizzate da olea europaea l. e loro uso genere specifico per la prevenzione delle patologie invecchiamento-correlate
US9073824B2 (en) 2012-01-26 2015-07-07 Prairie Pharms, Llc Method for cultivation of Monarda fistulosa for production of thymoquinone
KR101269490B1 (ko) * 2012-07-09 2013-05-30 연세대학교 산학협력단 세코이리도이드 글루코사이드 유도체를 유효성분으로 포함하는 탈모의 예방 또는 치료용 조성물
CN102942605B (zh) * 2012-11-30 2016-06-15 沈阳药科大学 清香藤中环烯醚萜类化合物的制备方法及其应用
CN104784241A (zh) * 2014-01-22 2015-07-22 上海御先医药科技有限公司 一种橄榄树叶粗提物的新用途
CN104473949A (zh) * 2014-11-11 2015-04-01 济南星懿医药技术有限公司 一种治疗肝癌的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4139196A (en) * 1994-11-07 1996-05-31 William R. Fredrickson Method and composition for antiviral therapy
WO2000004794A1 (en) * 1998-07-23 2000-02-03 Creagri, Inc. Water-soluble extract from olives
US6358542B2 (en) * 1999-12-20 2002-03-19 Usana, Inc. Antioxidant compositions extracted from olives and olive by-products
AU2000258901A1 (en) * 2000-04-06 2001-10-23 Nicholas V. Perricone Treatment of skin damage using olive oil polyphenols
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders

Also Published As

Publication number Publication date
EP1397105B1 (en) 2006-07-26
ATE333882T1 (de) 2006-08-15
ES2266512T3 (es) 2007-03-01
PT1397105E (pt) 2006-12-29
DE60213407T2 (de) 2007-08-23
JP2005508856A (ja) 2005-04-07
CN1315479C (zh) 2007-05-16
AU2002311985B9 (en) 2008-07-10
WO2002094193A1 (en) 2002-11-28
CA2447231A1 (en) 2002-11-28
US6632798B2 (en) 2003-10-14
BR0209922A (pt) 2004-07-27
IL158899A0 (en) 2004-05-12
CN1531435A (zh) 2004-09-22
AU2002311985B2 (en) 2008-04-10
EP1397105A1 (en) 2004-03-17
US20030004117A1 (en) 2003-01-02
DE60213407D1 (de) 2006-09-07
ZA200308763B (en) 2004-05-26
MXPA03010528A (es) 2005-04-19

Similar Documents

Publication Publication Date Title
DK1397105T3 (da) Præparat til inhibering af angiogenese
ATE324444T1 (de) Tek-antagonisten
DZ3402A1 (fr) Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
TR200200381T2 (tr) Pirimidin-2,4,6-Trion Metalloproteinaz İnhibitorler.
BG105880A (en) Compounds useful as anti-inflammatory agents
ATE405269T1 (de) Cyclohexylverbindungen als ccr5-antagonisten
BG105653A (en) Aromatic heterocyclic compounds as anti-inflammatory agents
WO2004078712A3 (en) Isoquinoline derivatives and methods of use thereof
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
EA200900663A1 (ru) Лечение синдрома "сухого глаза"
WO2003091259A8 (en) Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
MXPA04004301A (es) Bencimidazoles sustituidos utiles como inhibidores de la proteina cinasa.
ATE296283T1 (de) Zelladhäsion- und entzündungshemmende immunosuppressive verbindungen
AU2003300911A1 (en) Heterocyclic compounds as ccr5 antagonists
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
TW200716616A (en) Modulators of CCR-5 activity
MXPA02011858A (es) Inhibidores de adhesion de celula mediada por alfabeta2.
BR0010546A (pt) Terapia antiinflamatória para infecção mediada inflamatória
DK1150704T3 (da) Melagatran til behandling af betændelse
WO2004053067A3 (en) Methods for inhibiting cancer and scar formation
DE60213802D1 (de) Cak inhibitoren und deren verwendungen
BR0208655A (pt) Composição farmacêuticas